Emma R. Brannon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emma R. Brannon has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Catherine S. Johnson
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
12 shared publications - Deanna D. Mosley
Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, Omaha, NE 68198, USA
12 shared publications - Diane Costanzo-Garvey
Eppley Institute for Research in Cancer & Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA
12 shared publications - Elijah F. Edmondson
Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA
12 shared publications - Grinu Mathew
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
12 shared publications - Jeremy Steven Frieling
Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
12 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Bone metastasis continues to be the greatest challenge in treating patients with prostate cancer despite ongoing research. In bone, prostate cancer tumors hijack normal bone remodeling processes to drive cancer progression. However, it is unclear how these interactions drive bone-metastatic prostate cancer growth in the bone environment. To understand the mechanisms associated with bone-metastatic prostate cancer regulation of mesenchymal stem cells (MSC), we previously identified that bone-metastatic prostate cancer induces MSC expression of the pro-inflammatory chemokine CXCL8 and its mouse functional homologue Cxcl1. To date, there has been little to no information about the role of CXCL1/8 in MSC biology and its impact in the tumor–bone environment. Using genetic deletion of Cxcl1, we discovered a novel role for Cxcl1/8 in regulating MSC osteoblast differentiation, such that targeted deletion of Cxcl1 enhanced MSC osteoblastogenesis. Despite the osteogenic nature of prostate cancer, co-injection of Cxcl1 knockout (KO) MSCs with bone-metastatic prostate cancer in bone significantly suppressed tumor growth compared with co-injection with scrambled control (non-targeting) MSCs, even in the presence of three times more prostate cancer to MSCs. Furthermore, bulk RNA sequencing revealed immune response pathways, both in Cxcl1-KO MSCs and bone-metastatic prostate cancer tumors containing Cxcl1-KO MSCs. In support of this, Cxcl1-KO MSCs reduced immature neutrophils in the bone environment, while increasing monocytes. These findings demonstrate the importance of MSC-derived Cxcl1 in the bone microenvironment and highlight the importance of Cxcl1 in bone-metastatic prostate cancer progression.Implications:MSC-derived Cxcl1 regulates prostate cancer progression in bone.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Bone metastasis continues to be the greatest challenge in treating patients with prostate cancer despite ongoing research. In bone, prostate cancer tumors hijack normal bone remodeling processes to drive cancer progression. However, it is unclear how these interactions drive bone-metastatic prostate cancer growth in the bone environment. To understand the mechanisms associated with bone-metastatic prostate cancer regulation of mesenchymal stem cells (MSC), we previously identified that bone-metastatic prostate cancer induces MSC expression of the pro-inflammatory chemokine CXCL8 and its mouse functional homologue Cxcl1. To date, there has been little to no information about the role of CXCL1/8 in MSC biology and its impact in the tumor–bone environment. Using genetic deletion of Cxcl1, we discovered a novel role for Cxcl1/8 in regulating MSC osteoblast differentiation, such that targeted deletion of Cxcl1 enhanced MSC osteoblastogenesis. Despite the osteogenic nature of prostate cancer, co-injection of Cxcl1 knockout (KO) MSCs with bone-metastatic prostate cancer in bone significantly suppressed tumor growth compared with co-injection with scrambled control (non-targeting) MSCs, even in the presence of three times more prostate cancer to MSCs. Furthermore, bulk RNA sequencing revealed immune response pathways, both in Cxcl1-KO MSCs and bone-metastatic prostate cancer tumors containing Cxcl1-KO MSCs. In support of this, Cxcl1-KO MSCs reduced immature neutrophils in the bone environment, while increasing monocytes. These findings demonstrate the importance of MSC-derived Cxcl1 in the bone microenvironment and highlight the importance of Cxcl1 in bone-metastatic prostate cancer progression.Implications:MSC-derived Cxcl1 regulates prostate cancer progression in bone.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
CXCL1/8 KD Increases MSC Osteoblast Differentiation
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
CXCL1/8 KD Increases MSC Osteoblast Differentiation
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs Promote BM-PCa Osteogenesis In Vivo
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs Promote BM-PCa Osteogenesis In Vivo
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs suppresses C42B growth and regulates the immune environment
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs suppresses C42B growth and regulates the immune environment
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
GSEA of Cxcl1 KD shRNA MSCs RNA Sequencing Results
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
GSEA of Cxcl1 KD shRNA MSCs RNA Sequencing Results
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 regulates PCa proliferation and receptor expression
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 regulates PCa proliferation and receptor expression
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs Have Altered Collagen and ECM Pathway
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs Have Altered Collagen and ECM Pathway
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
SgRNA sequences for Generation of Cxcl1 KO MSCs
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
SgRNA sequences for Generation of Cxcl1 KO MSCs
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs suppress RM1 proliferation
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer
Cxcl1 KO MSCs suppress RM1 proliferation